PKU HealthCare Corp., Ltd.

Primary Objective: To conduct a bioequivalence study comparing the bioequivalence of oseltamivir phosphate capsules (75 mg) manufactured by Peking University Medicine Co., Ltd. as the test formulation and oseltamivir phosphate capsules (trade name: Tamiflu, strength: 75 mg) owned by Roche Pharma (Schweiz) AG as the reference formulation, under fasting and postprandial conditions, for a single dose. Secondary Objective: To evaluate the safety of a single oral dose of the test formulation (oseltamivir phosphate capsules, T) and the reference formulation (Tamiflu, R) in healthy adult participants in China.

Primary objective: To investigate the pharmacokinetic parameters and relative bioavailability of utpatinib extended-release tablets (trade name: RINVOQ®) manufactured by AbbVie Ireland NL B.V. under fasting and postprandial conditions using utpatinib extended-release tablets developed by Peking University Medicine Co., Ltd. as the test formulation and RINVOQ® as the reference formulation, owned by AbbVie Deutschland GmbH & Co. KG. Secondary objective: To evaluate the safety of single oral administration of utpatinib extended-release tablets (test and reference formulations) under fasting and postprandial conditions in healthy Chinese participants.

This study aimed to investigate the pharmacokinetic characteristics of a single-dose, fasting oral administration of febuxostat tablets (40 mg) developed and manufactured by Peking University Pharmaceutical Co., Ltd. as the test formulation and febuxostat tablets (40 mg) certified by TEIJIN PHARMA LIMITED as the reference formulation; and to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ between the two formulations.